Repaid $6.7 billion of debt following the $9.5 billion OxyChem divestiture.
Operating cash flow from continuing operations decreased 40% year-over-year.
Completed sale of OxyChem to Berkshire Hathaway for $9.5 billion.
Continuing operations income fell 70% YoY, excluding one-time gains.
The Q1 2026 report presents a company in the midst of a high-stakes transition. On one hand, the massive liquidity event from the OxyChem sale provides a critical lifeline, slashing debt and providing the cash necessary to stabilize the balance sheet. On the other hand, the underlying operational metrics show a marked decline in cash flow and continuing-operations earnings, highlighting the volatility of the energy market and the pressure of high fixed costs. For investors, the central tension lies in whether the one-time windfall from the divestiture is sufficient to bridge the gap until the core business recovers. While the path to $10 billion in debt is clearer, the shrinking operating cash flow may delay the return of capital to shareholders via buybacks. The overall impact of the filing is a significant reduction in financial risk through debt repayment, tempered by a sobering look at the current headwinds facing the company's primary oil and gas assets.